Edmund Mickunas Named Vice President of Regulatory for Advanced Cell Technologies

Before joining Applied Genetic Technologies, he was Vice President, Regulatory, Quality and Clinical Affairs for Oragenics, a company engaged in the development of vaccines, biologics and pharmaceuticals. Mr. Mickunas was previously Senior Director of Regulatory Affairs and Compliance for Control Delivery Systems, Inc., where he managed the submissions of IND filings, among other responsibilities. He also held senior regulatory positions at Bioheart, Inc., Cytomed and Del Laboratories. He received his B.S. and pursued graduate studies in human biochemistry at Fairleigh Dickinson University, as well as a Masters Degree from Fairfield University.

"We are pleased that Ed has elected to join us as his extensive regulatory expertise and experience in filing IND's will be invaluable as we prepare to file our first IND with the FDA in the second half of this year," said William M. Caldwell IV, Chairman & CEO of Advanced Cell. "Ed's most recent assignment focused on retinal programs. He has strong relations with the Ophthalmology Departments of our clinical advisors as well as recent first hand experience with processing retinal IND applications through the FDA. We look forward to his input and to his role in helping to move our stem cell therapeutic programs into and through the clinical process."

Before joining Applied Genetic Technologies, he was Vice President, Regulatory, Quality and Clinical Affairs for Oragenics, a company engaged in the development of vaccines, biologics and pharmaceuticals. Mr. Mickunas was previously Senior Director of Regulatory Affairs and Compliance for Control Delivery Systems, Inc., where he managed the submissions of IND filings, among other responsibilities. He also held senior regulatory positions at Bioheart, Inc., Cytomed and Del Laboratories. He received his B.S. and pursued graduate studies in human biochemistry at Fairleigh Dickinson University, as well as a Masters Degree from Fairfield University.

"I look forward to joining ACT at such an exciting time in the Company's development," said Mr. Mickunas. "I am impressed that despite a challenging economic and political environment, the Company has been able to acquire and develop such a promising regenerative medicine platform and to advance it to an industry leading stage of clinical development. I feel very privileged to be working with Dr. Lanza, a well respected leader in the field of regenerative medicine and Mr. Caldwell, whose financial experience is setting the Company on sound footing to make the clinical development of these very significant biotechnology platforms possible."

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future ability to draw on the credit Facility, future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the Company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: the Company's ability to meet all of the conditions to allow it to access the entire amount available under the credit Facility discussed in this press release, limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-K for the year ended December 31, 2009. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

SOURCE: Advanced Cell Technology, Inc.

CEOcast, Inc. 
Dan Schustack, 212-732-4300